BMKDF (Biomark Diagnostics) FCF Margin %: 7,360.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMKDF Biomark Diagnostics Inc BMKDF
24 GF Score
Price $0.38
! 4 Warning Signs
View Full Analysis

What is Biomark Diagnostics FCF Margin %?

Biomark Diagnostics BMKDF 24 FCF Margin % is 7,360.00% as of Mar. 2026. GuruFocus rates BMKDF with a GF Score™ of 24/100. The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Biomark Diagnostics ranks worse than 95.57% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biomark Diagnostics's Free Cash Flow for the three months ended in Mar. 2026 was $0.37 Mil. Biomark Diagnostics's Revenue for the three months ended in Mar. 2026 was $0.01 Mil. Therefore, Biomark Diagnostics's FCF Margin % for the quarter that ended in Mar. 2026 was 7,360.00%.

As of today, Biomark Diagnostics's current FCF Yield % is -1.86%.

The historical rank and industry rank for Biomark Diagnostics's FCF Margin % or its related term are showing as below:

BMKDF' s FCF Margin % Range Over the Past 10 Years
Min: -2870.45   Med: -658.93   Max: -173
Current: -1795.45


During the past 13 years, the highest FCF Margin % of Biomark Diagnostics was -173.00%. The lowest was -2870.45%. And the median was -658.93%.

BMKDF's FCF Margin % is ranked worse than
95.57% of 203 companies
in the Medical Diagnostics & Research industry
Industry Median: -0.96 vs BMKDF: -1795.45


Biomark Diagnostics FCF Margin % Related Terms


Biomark Diagnostics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Biomark Diagnostics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomark Diagnostics FCF Margin % Chart

Biomark Diagnostics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,851.43 -600.00 -607.50 -714.02 -1,811.36

Biomark Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,166.67 -724.14 -7,100.00 -11,860.00 7,360.00

BMKDF vs TMO, DHR, IDXX: FCF Margin % Comparison

For the Diagnostics & Research subindustry, Biomark Diagnostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomark Diagnostics FCF Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's FCF Margin % falls into.


BMKDF
24GF Score
Biomark Diagnostics Inc BMKDF
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biomark Diagnostics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Biomark Diagnostics's FCF Margin for the fiscal year that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-0.797/0.044
=-1,811.36 %

Biomark Diagnostics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=0.368/0.005
=7,360.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 7,360.00% mean?
Biomark Diagnostics (BMKDF) has a FCF Margin % of 7,360.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biomark Diagnostics and its competitors. According to the industry distribution chart, Biomark Diagnostics ranks #194 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 95.6%.
Is Biomark Diagnostics' FCF Margin % too high?
Biomark Diagnostics' current FCF Margin % is 7,360.00%. Based on the distribution chart, Biomark Diagnostics ranks #194 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Biomark Diagnostics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomark Diagnostics ranks #194 out of 203 companies for FCF Margin %. This places Biomark Diagnostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Biomark Diagnostics and its competitors. Biomark Diagnostics's current FCF Margin % is 7,360.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (BMKDF) has a current FCF Margin % of 7,360.00%. The current FCF Margin % is 7,360.00%. Biomark Diagnostics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Biomark Diagnostics (BMKDF), the current FCF Margin % is 7,360.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomark Diagnostics Business Description

Other Exchanges 20B:GermanyBUX:Canada
Address 130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
24GF Score

Get the complete analysis for BMKDF

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.38
Price